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in any medium, provided the original work is properly citeActivation of inflammatory pathways in the endothelium contributes to vascular
diseases, including sepsis and atherosclerosis. We demonstrate that miR-146a
and miR-146b are induced in endothelial cells upon exposure to pro-
inflammatory cytokines. Despite the rapid transcriptional induction of the
miR-146a/b loci, which is in part mediated by EGR-3, miR-146a/b induction is
delayed and sustained compared to the expression of leukocyte adhesion
molecules, and in fact coincides with the down-regulation of inflammatory gene
expression. We demonstrate that miR-146 negatively regulates inflammation.
Over-expression of miR-146a blunts endothelial activation, while knock-down of
miR-146a/b in vitro or deletion ofmiR-146a in mice has the opposite effect. MiR-
146 represses the pro-inflammatory NF-kB pathway as well as the MAP kinase
pathway and downstream EGR transcription factors. Finally, we demonstrate
that HuR, an RNA binding protein that promotes endothelial activation by
suppressing expression of endothelial nitric oxide synthase (eNOS), is a novel
miR-146 target. Thus, we uncover an important negative feedback regulatory
loop that controls pro-inflammatory signalling in endothelial cells that may
impact vascular inflammatory diseases.INTRODUCTION
The endothelium plays a central role in the pathogenesis of
vascular inﬂammatory diseases such as sepsis (Aird, 2003) and
atherosclerosis (Gimbrone & Garcia‐Cardena, 2012; Pober &
Sessa, 2007). During sepsis, massive circulating levels of pro‐th Network, Toronto,
ology, University of
ence in Cardiovascu-
y, Pasadena, CA
The Hospital for Sick
f Toronto, Toronto,
1 416 581 7484;
Ltd on behalf of EMBO. Thi
C BY 3.0), which permits u
d.inﬂammatory cytokines activate the endothelium and drive
pathological vascular permeability and tissue oedema, which lead
to acute organ dysfunction (Aird, 2003). Blocking endothelial
activation can limit mortality in mouse models of sepsis (London
et al, 2010). Endothelial activation also plays a pervasive role
in atherosclerosis, a chronic vascular inﬂammatory disorder that
is characterized by vessel narrowing, thrombosis and occlusion
(Gimbrone & Garcia‐Cardena, 2012; Pober & Sessa, 2007). Cell‐
surface expression of leukocyte adhesion molecules such
as vascular cell adhesion molecule‐1 (VCAM‐1), intercellular
adhesion molecule‐1 (ICAM‐1) and E‐Selectin, and secretion of
chemokines such as monocyte chemoattractant protein‐1 (MCP‐
1), facilitates the binding of circulating monocytes to the blood
vessel wall. Following transmigration into the intima, these cells
mature into inﬂammatory macrophages, and their secretion of
pro‐inﬂammatory cytokines further promotes endothelial activa-
tion, and serves to drive a feed‐forward loop that perpetuates
leukocyte recruitment (Pober & Sessa, 2007). Identifying
molecules that negatively regulate inﬂammatory pathways ins is an open access article under
se, distribution and reproduction
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treatment of acute or chronic vascular inﬂammatory diseases.
Activation of pro‐inﬂammatory transcriptional programs
such as the NF‐kB signalling pathway (Gareus et al, 2008;
Ruland, 2011; Ye et al, 2008) and the mitogen‐activated protein
kinase (MAPK)/early growth response (EGR) pathway (Hajra
et al, 2000; Shin et al, 2009; Wieland et al, 2005; Yan et al, 2000)
can cooperatively drive endothelial activation and vascular
inﬂammation. Considering that prolonged or exaggerated
inﬂammatory responses are detrimental, it is not surprising
that cellular negative feedback loops act to control the duration
and intensity of an inﬂammatory response (Ruland, 2011). For
example, activation of the NF‐kB pathway leads to the induction
of IkB proteins, which bind to NF‐kB proteins in the nucleus and
exports them to the cytoplasm (Arenzana‐Seisdedos et al, 1995).
EGR transcription factors also induce the expression of their
own repressor proteins (Kumbrink et al, 2005). In addition to
feedback regulation at the level of transcription, microRNAs
have recently been identiﬁed that serve in post‐transcriptional
negative feedback loops that modulate inﬂammatory signalling.
MicroRNAs bind to the 30 UTRs of target mRNAs and inhibit
their translation and/or stability (Bartel, 2009). MiR‐146a was
previously found to be transcriptionally induced by NF‐kB
in response to activation of innate immune signalling in
monocytes (Taganov et al, 2006). MiR‐146a targets the adaptor
proteins TRAF6 and IRAK1/2 (Bhaumik et al, 2008; Hou
et al, 2009; Nahid et al, 2009; Taganov et al, 2006) and can
inhibit activation of the NF‐kB pathway (Bhaumik et al, 2008;
Zhao et al, 2011), suggesting that miR‐146a participates in a
negative feedback loop to control NF‐kB signalling in mono-
cytes. However, the function ofmiR‐146a/b is poorly understood
in endothelial cells.
We previously identiﬁed miR‐146a and miR‐146b as being
enriched in endothelial cells isolated from differentiating
embryonic stem cells (Fish et al, 2008). Herein we demonstrate
that miR‐146a and miR‐146b are enriched in endothelial cells
in vivo and that they are strongly induced in endothelial cells
in response to pro‐inﬂammatory cytokines. We also identify
a novel transcriptional pathway involving EGR proteins
that participates in the induction of miR‐146a and miR‐146b.
Through delayed induction kinetics, miR‐146a/b appear to act
as negative feedback regulators of inﬂammatory signalling in
endothelial cells. MiR‐146 inhibits endothelial activation by
dampening the activation of pro‐inﬂammatory transcriptional
programs, including the NF‐kB, AP‐1 andMAPK/EGR pathways,
likely through regulation of IL‐1b signalling pathway adaptor
proteins (i.e., TRAF6, IRAK1/2). In addition, miR‐146 modulates
post‐transcriptional pro‐inﬂammatory pathways via targeting
of the RNA binding protein HuR. We provide evidence that
HuR facilitates endothelial activation by repressing expression
of endothelial nitric oxide synthase (eNOS), a major source
of nitric oxide, which potently inhibits leukocyte adhesion
(Kubes et al, 1991). Thus miR‐146 represses both transcriptional
and post‐transcriptional activation of the inﬂammatory program.
Our results reveal a potent anti‐inﬂammatory action of
miR‐146a/b in the endothelium and suggest that therapeutic
elevation of this microRNA family may be a useful treatment 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.strategy for vascular inﬂammatory diseases, including sepsis
and atherosclerosis.RESULTS
Induction of miR‐146a and miR‐146b (miR‐146a/b) by
inﬂammatory stimuli in endothelial cells
Treatment of human umbilical vein endothelial cells (HUVEC)
with the pro‐inﬂammatory cytokine, IL‐1b, induced the rapid
induction of mRNAs encoding leukocyte adhesion molecules,
such as VCAM‐1, E‐Selectin and ICAM1 (Fig 1A). We next
measured levels of miR‐146a and miR‐146b. Since miR‐146a and
miR‐146b differ by only two nucleotides near their 30 ends,
we designed primers that ampliﬁed only miR‐146a or miR‐146b
(see Materials and Methods Section). We found that these
microRNAs were dramatically induced in response to IL‐1b
treatment (Fig 1B). Similar induction of miR‐146a/b was
observed following tumor necrosis factor‐a (TNF‐a) treatment
(Supporting Information Fig S1). MiR‐146a/b levels were
increased during the late stages of an inﬂammatory response
(i.e., 8–72 h post‐treatment), but levels were only modestly
elevated at early stages (i.e., 1–4 h post‐treatment; Fig 1B,
Supporting Information Fig S1). Interestingly, the induction of
miR‐146a/b coincided with the down‐regulation of adhesion
molecule genes (Fig 1A and B). Quantiﬁcation of miR‐146a/b
levels revealed that miR‐146a was expressed 9‐fold higher
than miR‐146b in unstimulated cells, and 3‐fold higher than
miR‐146b in IL‐1b‐treated cells (Fig 1C). We next measured
the transcription of the miR‐146a and miR‐146b genomic loci.
MiR‐146a is processed from a two‐exon non‐protein coding
mRNA transcript on chromosome 5, and we therefore measured
unspliced pre‐mRNA of this transcript as a surrogate of
transcription [as we have done previously (Fish et al, 2010)].
MiR‐146b is processed from a single exon transcript on
chromosome 10, and primers were designed to measure the
levels of this transcript. We found that transcription of miR‐146a
andmiR‐146bwere rapidly (within 1 h) and dramatically (40‐ and
20‐fold, respectively) induced in response to IL‐1b (Fig 1D). The
transcription of miR‐146a and miR‐146b was sustained for the
duration of IL‐1b treatment. This is in contrast to VCAM‐1, SELE
(E‐Selectin) and ICAM‐1 mRNA, which were down‐regulated
after 8 h of IL‐1b treatment. Despite the rapid transcription
of the miR‐146a and miR‐146b genes, delayed expression of
mature microRNAs implies inefﬁcient or delayed processing of
miR‐146a/b in cytokine‐stimulated endothelial cells.
MiR‐146a/b expression is sustained following removal of
pro‐inﬂammatory cytokines
To determine the stability of the IL‐1b‐mediated induction of
miR‐146a/b we treated endothelial cells with IL‐1b for 24 h and
then removed the cytokine. In contrast to inﬂammatory genes
such as VCAM‐1 and SELE, which were rapidly down‐regulated
upon removal of IL‐1b (Fig 2A), miR‐146a/b remained elevated
for more than 2 days (Fig 2B). MiR‐146b expression was
especially long‐lived. While the levels of pri‐miR‐146a decreased
following the removal of IL‐1b, levels of pri‐miR‐146b remainedEMBO Mol Med (2013) 5, 1017–1034
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Figure 1. MiR‐146a and miR‐146b are induced in response to interleukin‐1b (IL‐1b) treatment of endothelial cells.
A. Levels of pro-inflammatory genes (VCAM-1, SELE (E-Selectin), ICAM1) were measured in IL-1b-treated human umbilical vein endothelial cells (HUVEC) by
quantitative reverse transcriptase real-time PCR (qRT-PCR), revealing that these inflammatory genes were rapidly induced by IL-1b, but decreased by 24 h (h).
Data represent the mean  SEM of three independent experiments.
B. Levels of mature miR-146a and miR-146b were assessed by qRT-PCR (n ¼ 3). MiR-146a/b were increased following prolonged treatment with IL-1b.
C. The copy numbers of miR-146a and miR-146b were quantified in non-stimulated (NS) and 72 h IL-1b-treated endothelial cells (n ¼ 3).
D. Assessment of the primary transcripts (pri-cursors), pri-miR-146a and pri-miR-146b, by qRT-PCR demonstrated rapid transcriptional up-regulation, which
mirrored that of other inflammatory genes (n ¼ 5). The transcription of miR-146a/b appeared to be sustained during prolonged inflammation.
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locus is maintained following the removal of pro‐inﬂammatory
cytokines (Fig 2C). The induction of miR‐146a/b by IL‐1b
therefore appears to be highly stable, even in the absence of the
initiating stimulus.EMBO Mol Med (2013) 5, 1017–1034  2Over‐expression of miR‐146a inhibits the endothelial
inﬂammatory response
To assess the function of elevated levels of miR‐146 in
endothelial cells, we over‐expressed miR‐146a via transfection
of miR‐146a mimic. Over‐expression of miR‐146a in HUVEC013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1019
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Figure 2. MiR‐146a and miR‐146b expression is sustained after the
removal of IL‐1b. Endothelial cells were treated with IL-1b for 24 h, after
which IL-1bwas removed. Levels of VCAM-1 and SELE (A), mature miR-146a/b
(B) and pri-miR-146a/b (C) were monitored at various time-points after the
removal of IL-1b by qRT-PCR. While VCAM-1 and SELE rapidly returned to
base-line levels, miR-146a/b levels remained elevated. The transcription of
miR-146a decreased by 24 h after removal of IL-1b, while transcription of
miR-146b was sustained in the absence of IL-1b. Data represents the
mean  SEM of three independent experiments. Statistical analyses were
performed using t-test to compare post-IL-1b removal time-points to 24 h
of IL-1b treatment (i.e., time zero). Significant p-values (from left to right)
in (A) are 0.0004, <0.0001, 0.0004, <0.0001, 0.0006 and 0.0001,
respectively. p-value in (B) is 0.049. p-Values in (C) are 0.012, 0.001 and 0.001,
respectively.
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target of miR‐146 (Taganov et al, 2006). Next we assessed the
expression of several pro‐inﬂammatory genes (VCAM‐1, ICAM‐1,
SELE andMCP‐1) by qRT‐PCR, and found that the basal levels of
these mRNAs were suppressed in unstimulated miR‐146a over‐
expressing cells (Fig 3B, left). Importantly, miR‐146a over‐
expression also dampened the induction of these inﬂammatory
genes in response to IL‐1b treatment (Fig 3B, right). Nitric oxide
(NO) generated by eNOS potently inhibits leukocyte adhesion
to the endothelium (Kubes et al, 1991), and eNOS (NOS3) is
known to be transcriptionally (Anderson et al, 2004) and post‐
transcriptionally (Yoshizumi et al, 1993) repressed following
treatment of endothelial cells with pro‐inﬂammatory cytokines.
The level of NOS3 mRNA in unstimulated cells over‐expressing
miR‐146awas elevated (Fig 3B, left). After 8 h of IL‐1b treatment,
NOS3 mRNA was decreased by 45.0  6.5% (p ¼ 0.004,
not shown). Over‐expression of miR‐146a blunted this IL‐1b‐
dependent decrease in NOS3 mRNA levels (Fig 3B, right).
Western blotting conﬁrmed that the induction of VCAM‐1,
E‐Selectin and ICAM‐1 protein was inhibited in miR‐146a over‐
expressing cells (Fig 3C), and that the loss of eNOS expression
was blunted (Fig 3D). Consistent with a reduction in inducible
adhesion molecule expression and an increase in eNOS protein,
miR‐146a over‐expression in HUVEC reduced the number of
THP‐1 monocytes that adhered to IL‐1b‐treated endothelial cells
(Fig 3E). Over‐expression of miR‐146a in aortic endothelial
cells also inhibited leukocyte adhesion (Supporting Information
Fig S2), suggesting that miR‐146a broadly represses endothelial
activation. MiR‐146a therefore inhibits the endothelial inﬂam-
matory response, including the induction of adhesion molecules
and chemoattractants and the loss of eNOS expression.
Endogenous miR‐146 inhibits the endothelial inﬂammatory
response
We next utilized a miR‐146 locked‐nucleic acid (LNA) inhibitor
to assess the function of endogenous miR‐146 in endothelial
cells. In addition to reducing the level of mature miR‐146a by
81.7  6.5%, this inhibitor also reduced the level of miR‐146b
by 92.5  2.7% (not shown), likely owing to the limited (two
nucleotide) difference in sequence between miR‐146a and miR‐
146b. Treatment with miR‐146 inhibitor elevated the level of the
miR‐146 target, TRAF6 (Fig 4A). Additionally, miR‐146 inhibitor
increased the basal levels of VCAM‐1 mRNA, and had a potent
effect on the IL‐1b‐inducible expression of VCAM‐1, ICAM‐1,
SELE and MCP‐1 (Fig 4B). Endogenous miR‐146 appeared to
restrain the intensity as well as the duration of the inﬂammatory
response, since these inﬂammatory genes remained at elevated
levels 24 h after IL‐1b treatment (Fig 4B). In addition, the
decrease in eNOS (NOS3) mRNA that was observed after a 24 h
treatment with IL‐1b was augmented by miR‐146 inhibitor
(Fig 4C). Western blotting conﬁrmed that the loss of eNOS
protein in response to IL‐1b treatment was enhanced bymiR‐146
inhibition (Fig 4D) and that IL‐1b‐inducible VCAM‐1, E‐Selectin
and ICAM‐1 protein expression was greatly enhanced by
miR‐146 inhibition (Fig 4E). Finally, inhibition of miR‐146 in
endothelial cells enhanced the adhesion of THP‐1 monocytes
following IL‐1b treatment (Fig 4F).EMBO Mol Med (2013) 5, 1017–1034
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Figure 3. MiR‐146a over‐expression represses the endothelial inﬂammatory response.
A. MiR-146a was over-expressed in endothelial cells by transfection of miR-146a mimic and levels of a known target of miR-146, TRAF6, were assessed by
Western blot. GAPDH was used as a loading control and densitometry is indicated above. A representative experiment is shown.
B. Expression of TRAF6 (white bar), inflammatory genes (VCAM-1, ICAM1, SELE (E-Selectin), and MCP-1; black bars), as well as NOS3 (eNOS; grey bar), were
measured in unstimulated (left) and IL-1b-stimulated cells (right) by qRT-PCR. For inflammatory genes, gene expression was analysed 1.5 h after addition of
IL-1b, while NOS3was assessed after 8 h. Data is presented as mRNA levels in miR-146a mimic-transfected cells compared to control mimic-transfected cells,
with the dotted line indicating a ratio of 1 (i.e., no change; n ¼ 4). p Values (t-test) from left to right are 0.031, 0.023, 0.0002, 0.0001, 0.002, 0.014, 0.006,
0.012, 0.012, 0.006, 0.011 and 0.045, respectively.
C. Western blotting was performed to measure expression of VCAM-1, E-Selectin and ICAM-1 protein in control and miR-146a mimic-transfected cells.
Densitometry is indicated.
D. Western blotting of eNOS protein was performed in control and miR-146a mimic-transfected cells.
E. Adhesion of the mononuclear cell line, THP-1, to unstimulated and IL-1b-treated endothelial cells transfected with control or miR-146a mimic was visualized
(left) and quantified (right), revealing a strong anti-adhesive effect of miR-146a over-expression. Scale bar is 200 mm. Shown is a representative experiment
(mean  SEM) with three replicate wells and three images per well for each condition. ANOVA, p < 0.0001. Indicates a significant difference between
IL-1b-treated control and miR-146a mimic-transfected cells, p < 0.001.
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growth response (EGR) pathways
MiR‐146 targets TRAF6, IRAK1 and IRAK2 (Hou et al, 2009;
Taganov et al, 2006), which are key adaptor molecules of the
IL‐1b signal transduction pathway. Several signalling pathways
are activated downstream of TRAF6/IRAK1/2 including the
NF‐kB, p42/p44 MAPK and JNK/AP‐1 pathways. We found that
miR‐146a over‐expression inhibited the IL‐1b‐mediated induc-
tion of an NF‐kB‐dependent reporter in endothelial cells, while
inhibiting miR‐146 enhanced NF‐kB activity in response to IL‐1b
treatment (Fig 5A). In addition, we assessed the activation of the
p42/p44 MAPK pathway by measuring the levels of phosphory-
lated ERK (pERK). Levels of pERKwere reduced in unstimulated
miR‐146a over‐expressing cells, and the induction of pERK in
response to IL‐1b was also inhibited (Fig 5B, top). In contrast,
pERK levels were enhanced in cells treated with miR‐146
inhibitor (Fig 5B, bottom). EGR transcription factors are induced
downstream of MEK (MAPKK) in the p42/p44 MAPK pathway
(Saleem et al, 1995). We assessed the expression of EGR‐1 and
EGR‐3 in response to IL‐1b treatment and found that EGR‐1 and
EGR‐3 were potently induced after only 1 h of IL‐1b, and that
EGR‐3 was induced to a greater extent than EGR‐1 (Fig 5C).
Consistent with the reduced levels of pERK, we found that miR‐
146a over‐expression inhibited the activation of EGR‐1 and EGR‐3
mRNA in response to IL‐1b, while miR‐146 inhibitors enhanced
the induction of EGR‐3 mRNA (Fig 5D). Interestingly, we found
that EGR‐3 was a predicted target of miR‐146 (Fig 5E). To
determine whether miR‐146 could directly repress EGR‐3 we
performed luciferase assays in which a region of the EGR‐3 30
UTR or a concatemer of the predicted miR‐146 binding site, were
inserted downstream of the luciferase open reading frame
(ORF). As a control, we assessed luciferase activity of constructs
bearing the TRAF6 30 UTR. While TRAF6 luciferase reporters
were highly repressed in response to miR‐146a over‐expression
(Fig 5E), EGR‐3 30 UTR (Supporting Information Fig S3) or
concatemer constructs (Fig 5E), were refractory to miR‐146‐
mediated repression. This suggests that miR‐146 does not
directly target EGR‐3, but that it instead represses activation of
EGR proteins via inhibition of upstream signal components (i.e.,
TRAF6/IRAK1/2). Finally, the activation of the AP‐1 pathway
also appeared to be modestly inhibited by miR‐146 since the
IL‐1b‐mediated induction of c‐Fos was reduced in cells over‐
expressing miR‐146a, while the induction of c‐Junwas enhanced
when miR‐146 was inhibited (Fig 5F).Figure 4. Endogenous miR‐146 restrains endothelial activation.
A. Endothelial cells were transfected with amiR-146 LNA inhibitor (which reduces
miR-146, TRAF6, was measured by Western blot.
B. The expression of inflammatory genes (VCAM-1, ICAM-1, SELE, and MCP-1) in
represents mean  SEM of three independent experiments. Significant p valu
C. Levels of NOS3 mRNA were assessed by qRT-PCR in control inhibitor and miR-
expressed relative to untreated cells.
D. Levels of eNOS protein were measured in control and miR-146 inhibitor tran
E. Western blotting was performed to measure VCAM-1, E-Selectin and ICAM-1 p
F. Monocyte adhesion assays were performed in control and miR-146 inhibitor
quantification of a representative experiment (three replicate wells, three im
Indicates a significant difference between IL-1b-treated control and miR-1
EMBO Mol Med (2013) 5, 1017–1034  2EGR proteins control the transcription of the miR‐146a/b
genes
Our data suggests that miR‐146a and miR‐146b may participate
in a negative feedback loop in endothelial cells to
restrain endothelial inﬂammation. MiR‐146a is known to be
NF‐kB‐responsive, whilemiR‐146b is not (Perry et al, 2009). We
found that miR‐146a can repress the NF‐kB signalling pathway
(Fig 5A), revealing a miR‐146a/NF‐kB negative regulatory loop
that acts to restrain inﬂammation in endothelial cells. To test
whether a miR‐146‐mediated negative feedback loop might also
involve EGR proteins, we antagonised the EGR pathway to
assess if this pathway regulates the transcription ofmiR‐146a/b.
Inhibition of the MAP kinase pathway with the MEK inhibitor,
U0126, repressed the rapid induction of EGR‐3 following a 1 h
treatment with IL‐1b (Fig 6A) and inhibited the induction of pri‐
miR‐146a and pri‐miR‐146b at the same early time‐point (Fig 6B).
Similarly, knock‐down of EGR‐3 by siRNA (Fig 6C) inhibited the
rapid transcriptional induction of both pri‐miR‐146a and pri‐miR‐
146b in response to IL‐1b (Fig 6D). To deﬁne the cis elements
that mediate this effect, we examined evolutionarily conserved
regions (ECRs) surrounding the miR‐146a and miR‐146b genes
for conserved EGR binding sites. No conserved EGR sites were
found in the ECRs surrounding the promoter ofmiR‐146a (10 kb
up‐ and down‐stream of the transcriptional start site of pri‐miR‐
146a), suggesting that the EGR site(s) that mediate induction of
miR‐146a transcription may act at a distance or act through a
non‐conserved or non‐canonical EGR site. However, a con-
served EGR site was identiﬁed in the miR‐146b promoter (858–
848 nucleotides upstream of the mature miR‐146b sequence;
chr.10:104,195,419–104,195–428, Fig 6E). The transcriptional
start site of pri‐miR‐146b is 700 nucleotides upstream of the
miR‐146b mature sequence (Taganov et al, 2006). This would
place this EGR site in the proximal promoter of miR‐146b.
Over‐expression of EGR‐3 resulted in robust induction of a miR‐
146b proximal promoter/reporter construct, and mutation of the
conserved EGR binding site in the miR‐146b promoter (Fig 6F)
eliminated this induction (Fig 6G). Furthermore, the miR‐146b
promoter was moderately responsive to IL‐1b stimulation, and
this effect was completely abrogated when the EGR binding
site was mutated (Fig 6H). Taken together these data suggest
that activation of the MAP kinase/EGR pathway regulates
the transcription of the miR‐146a/b loci, and that miR‐146 can
in turn repress the MAPK/EGR pathway; thereby forming a
negative feedback loop.levels of miR-146a andmiR-146b by>80%), and the level of a known target of
unstimulated and IL-1b-stimulated cells was assessed by qRT-PCR. Data
es (t-test) are indicated above.
146 inhibitor transfected cells after 24 h of IL-1b treatment (n ¼ 3). Data is
sfected cells.
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transfected endothelial cells. Representative images are shown (above) and
ages per well) is shown (below). Scale bar is 200 mm. ANOVA, p < 0.0001.
46 inhibitor-transfected cells, p < 0.001.
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Henry S. Cheng et al.MiR‐146 targets the RNA‐binding protein HuR to control
endothelial activation
HuR was previously found to promote endothelial activation in
response to LPS treatment of endothelial cells by facilitating NF‐
kB activation (Rhee et al, 2010). Interestingly, microRNA target
prediction programs (Targetscan and Pictar) suggested that HuR
might be a direct target of miR‐146 (Fig 7A, Fig. S4). We
conﬁrmed that luciferase constructs containing the HuR 30 UTR
could be repressed by miR‐146a (Fig 7B), and also found that
levels of HuR mRNA (Supporting Information Fig S5) and
protein (Fig 7C) were suppressed or elevated when miR‐146
was over‐expressed or knocked‐down in endothelial cells,
respectively. To test the functional importance of HuR in
IL‐1b‐mediated endothelial activation, we knocked down HuR
and measured the adhesion of THP‐1 cells to endothelial cells.
HuR knock‐down inhibited THP‐1 adhesion to IL‐1b treated
endothelial cells (Fig 7D). Additionally, HuR knock‐down also
inhibited THP‐1 adhesion to TNF‐a treated cells (Supporting
Information Fig S6), suggesting that HuR broadly facilitates
endothelial activation. To assess the contribution of HuR to the
enhanced adhesiveness of miR‐146 inhibitor‐treated endothelial
cells, we knocked‐down HuR, and were able to block the
increase in THP‐1 adhesion (Fig 7E). Interestingly, VCAM‐1,
ICAM‐1, SELE and MCP‐1 contain AU‐rich elements (AREs) in
their 30 UTRs (Supporting Information Fig S7). AREs can confer
instability to transcripts, which is antagonized by HuR binding to
these sites (Fan & Steitz, 1998). We therefore tested whether
HuR could regulate the expression of these inﬂammatory genes.
While VCAM‐1 and MCP‐1 were highly enriched in HuR
immunoprecipitates from IL‐1b‐treated cells (Supporting Infor-
mation Fig S8A), HuR knock‐down failed to affect the induction
of VCAM‐1 or MCP‐1 at the mRNA or protein level (Fig 7F,
Supporting Information Figs S8B, C, and S9B), suggesting that
they are not functional targets of HuR. Additionally, we found
that NF‐kB activity was not altered by HuR knock‐down
(Supporting Information Fig S8D), neither was the induction
of EGR‐3 (Supporting Information Fig S9B). This was in contrast
to knock‐down of another miR‐146 target, TRAF6, which
decreased NF‐kB activity (Supporting Information Fig S8D),
the induction of adhesion molecules and EGR transcription
factors (Fig 7F, Supporting Information Fig S9B). In contrast to
the lack of regulation of VCAM‐1/MCP‐1 by HuR, eNOS mRNAFigure 5. MiR‐146 inhibits the induction of NF‐kB, MAPK/EGR and AP‐1 path
A. The activity of a NF-kB promoter-luciferase reporter construct was assessed i
inhibitor or miR-146 inhibitor. MiR-146a over-expression reduced IL-1b-induce
activity. Data represents the mean  SEM of three independent experiments. AN
difference between the indicated groups, p < 0.01 and p < 0.001, respective
B. Activation of the MAP kinase pathway was assessed by measuring the levels o
loading control. MiR-146a over-expression inhibited the basal and IL-1b-indu
C. Induction of EGR-1 and EGR-3 in response to IL-1b was assessed by qRT-PCR,
D. MiR-146a over-expression inhibited the IL-1b-mediated induction of EGR-1 and
Significant p values (t-test) from left to right are 0.002, 0.004 and 0.022, res
E. Schematic of a potential miR-146 binding site in the 30 UTR of EGR-3 (top). Lucife
UTR sequences were performed in the presence of control or miR-146a mimi
F. Activation of the JNK/AP-1 pathway was assessed by measuring the induction
expression, while inhibition of miR-146 enhanced c-Jun expression in response
respectively.
EMBO Mol Med (2013) 5, 1017–1034  2and protein levels were elevated in HuR knock‐down cells and
eNOS was not down‐regulated in response to IL‐1b treatment of
these cells (Fig 7F and G). Knock‐down of TRAF6 did not affect
the basal levels of NOS3 mRNA, but did inhibit the down‐
regulation of NOS3 in response to IL‐1b (Fig 7F). Finally,
inhibition of nitric oxide activity by treatment with L‐NAME
negated the reduced adhesion in HuR knock‐down cells
(Fig 7H), suggesting that HuR regulates endothelial activation
by modulation of NO activity. These results suggest that miR‐
146 targets TRAF6/IRAK1/2 and HuR, which cooperate to
control endothelial activation through distinct pathways. While
TRAF6/IRAK1/2 affects NF‐kB transcriptional activity and
the induction of leukocyte adhesion molecules and chemo-
attractants, HuR affects NO‐dependent leukocyte adhesion.
MiR‐146a knock‐out mice have an exaggerated acute vascular
inﬂammatory response
Assessment of miR‐146a/b expression in blood vessels revealed
that this microRNA family is enriched in the endothelium
compared to cells in the vascular wall (Fig 8A). To assess the role
of miR‐146a in controlling endothelial activation in vivo, we
utilized miR‐146a/ mice (Boldin et al, 2011). MiR‐146a/
mice on a C57/BL6 background are phenotypically normal at
birth, but acquire chronic inﬂammation, including myeloprolif-
eration in the spleen and bone marrow and develop enlarged
spleens beginning around 5–6 months of age (Zhao et al, 2011).
We therefore utilized young mice (3–4 months of age) for our
experiments, since they do not appear to have an overt
inﬂammatory phenotype. MiR‐146a was expressed at much
higher levels than miR‐146b in the heart, and loss of miR‐146a
did not affect expression of miR‐146b, suggesting that miR‐146b
is likely unable to compensate for loss of miR‐146a (Fig 8B).
Additionally, we assessed the expression of several other
microRNAs that are known to modulate inﬂammatory signal-
ling, and found that these were not appreciably altered in
miR‐146a/ mice (Supporting Information Fig S10). Similar to
our ﬁndings using miR‐146 inhibitors in vitro, we found that
levels of HuR mRNA and protein were increased in the hearts
of miR‐146a/ mice (Fig 8C), suggesting that HuR is also a
target of miR‐146a in vivo. Levels of TRAF6 protein were also
highly elevated (Fig 8C). To determine the role of miR‐146a
in the regulation of an acute vascular inﬂammatory response,ways.
n endothelial cells transfected with control mimic, miR-146a mimic, control
d NF-kB-dependent promoter activity, while inhibition of miR-146 enhanced
OVA, p < 0.0001 for mimic and inhibitor data.  and  indicate a significant
ly.
f phosphorylated ERK (pERK) (p42/p44). Total levels of ERK2 were used as a
ced levels of pERK, while miR-146 inhibitor had the opposite effect.
demonstrating rapid and transient induction (n ¼ 3).
EGR-3, while inhibition of miR-146 enhanced the induction of EGR-3 (n ¼ 3).
pectively.
rase assays utilizing wild-type or seed-mutated EGR-3 concatemer or TRAF6 30
c (p ¼ 0.042, t-test, n ¼ 3).
of c-Fos and c-Jun by qRT-PCR. MiR-146a over-expression reduced c-Fos
to IL-1b (n ¼ 4). Significant p values (t-test) from left to right are 0.005, 0.024,
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Figure 6. The MAPK/EGR pathway regulates the transcription of miR-146a and miR-146b.
A. Treatment of endothelial cells with the MEK inhibitor, U0126, inhibited the basal expression (t-test, p ¼ 0.0003) and IL-1b-dependent induction (t-test,
p ¼ 0.037) of EGR-3 (n ¼ 3).
B. Induction of pri-miR-146a and pri-miR-146b by IL-1b was reduced in cells pre-treated with the MAP kinase inhibitor, U0126. Data represents the relative
induction of pri-miR-146a/b in cells treated with U0126 compared to cells treated with DMSO (vehicle) (n ¼ 4). p ¼ 0.037 for pri-miR-146a and p ¼ 0.010 for
pri-miR-146b (t-test).
C. EGR-3 knock-down by siRNA transfection reduced the basal (t-test, p < 0.0001) and IL-1b-induced levels (t-test, p ¼ 0.004) of EGR-3 (n ¼ 5).
D. The induction of pri-miR-146a and pri-miR-146b was also reduced in EGR-3 knock-down cells (n ¼ 5). p ¼ 0.023 for pri-miR-146a and p ¼ 0.013 for
pri-miR-146b (t-test).
E. Schematic indicating a potential EGR binding site (shaded area) in the miR-146b promoter. Sequence comparison between various species is indicated.
Asterisks indicate conserved nucleotides across all species.
F. Schematic of deletion of the EGR binding site in the miR-146b promoter.
G. AmiR-146b promoter-luciferase reporter was responsive to EGR-3 over-expression (OE) in bovine aortic endothelial cells (BAEC) and mutation of a conserved
EGR binding site abrogated this responsiveness. Data depicts the fold induction with EGR-3 OE compared to control. Shown is a representative experiment
(n ¼ 3 replicates). p ¼ 0.0017 (t-test).
H. A miR-146b promoter-luciferase reporter was modestly induced in response to IL-1b and this induction was not observed when the EGR site was mutated.
IL-1b was added at concentrations of 10, 20 or 40 ng/mL. Shown is a representative experiment (n ¼ 3 replicates). ANOVA, p ¼ 0.011.  and  indicate a
significant difference between the indicated groups, p < 0.05, p < 0.01, respectively.
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Henry S. Cheng et al.wild‐type and miR‐146a/ mice were injected with PBS or
IL‐1b and the expression of several inﬂammatory genes were
measured in harvested hearts. We found that the basal
expression of these genes in PBS‐injected mice was not altered
in miR‐146a/ mice compared to wild‐type mice (Fig 8D).
However, miR‐146a/ mice had enhanced expression of
Vcam‐1, Icam‐1, Sele, Mcp‐1, Egr‐1 and Egr‐3 in response to a
2 h IL‐1b treatment, and Icam‐1 and Sele remained signiﬁcantly
elevated at 4 h (Fig 8D). In contrast to markers of endothelial
activation, levels of eNOS (Nos3) mRNA tended to be lower
in miR‐146a/ mice, although this difference did not reach
statistical signiﬁcance (Supporting Information Fig S11A). Levels
of eNOS protein were also modestly reduced in miR‐146a/
mice (Supporting Information Fig S11B). Enhanced induction of
Vcam‐1 protein inmiR‐146a/mice was conﬁrmed byWestern
blotting (Fig 8E) and immunoﬂuorescence (Fig 8F). Vcam‐1
protein was predominantly increased in the endothelium,
although expression was also observed in regions immediately
adjacent to the endothelium. Taken together, these data
demonstrate that miR‐146a restrains endothelial activation
in vivo.DISCUSSION
Acute inﬂammation is essential for wound repair and for the
innate immune response to invading pathogens. However, the
intensity and duration of an acute inﬂammatory response must
be tightly regulated, especially considering that inﬂammation
has a detrimental effect on the function of the vasculature. For
example, an excessive inﬂammatory response during sepsis
results in organ failure and death due to profound and systemic
increases in endothelial cell permeability (London et al, 2010),
while chronic vascular inﬂammation drives the progression of
atherosclerosis (Pober & Sessa, 2007). We demonstrate here that
miR‐146a andmiR‐146b act to restrain the intensity and duration
of endothelial activation in response to pro‐inﬂammatory
cytokine stimulation. While miR‐146a over‐expression blunts
endothelial activation and recruitment of leukocytes in response
to IL‐1b treatment, knock‐down of miR‐146a/b in vitro has
the opposite effect. Importantly, miR‐146a/ mice display
enhanced induction of leukocyte adhesion molecules and
chemokines in response to IL‐1b treatment, demonstrating that
miR‐146a restrains vascular inﬂammation in vivo. We ﬁnd
that the anti‐inﬂammatory activity of miR‐146a/b is mediated
by suppression of pro‐inﬂammatory transcription factors (i.e.,
NF‐kB, EGR‐1/3, AP‐1) as well as through modulation of post‐
transcriptional pro‐inﬂammatory pathways (mediated by the
targeting of HuR).
MiR‐146a/b levels accumulate in the late stages of an
inﬂammatory response, when other inﬂammatory genes such
as VCAM‐1, ICAM‐1 and SELE are being down‐regulated (Fig 1),
and miR‐146a/b levels remain elevated for several days, even in
the absence of pro‐inﬂammatory cytokines (Fig 2). The initial
transcription of miR‐146a is mediated, to a large extent, by
NF‐kB (Taganov et al, 2006). We also identify a role for EGR‐3 in
the transcriptional regulation of both miR‐146a and miR‐146bEMBO Mol Med (2013) 5, 1017–1034  2(Fig 6). Since miR‐146a/b repress activation of the NF‐kB
and EGR pathways (Fig 5), miR‐146a/b induction in response to
pro‐inﬂammatory cytokines forms a negative feedback loop to
control endothelial activation. Curiously, the NF‐kB (Arenzana‐
Seisdedos et al, 1995) and EGR pathways (Fig 5C) are only
transiently active following induction of inﬂammation, yet the
transcription ofmiR‐146a/b is maintained in the late stages of an
inﬂammatory response (Fig 1D), and in the case of miR‐146b,
transcription is maintained even in the absence of cytokine
(Fig 2C). The pathways that mediate this continued transcription
are unknown. In addition, the mechanisms that control the
delayed appearance of mature miR‐146a/b during inﬂammation
are also not known.
Considering the kinetics of miR‐146 induction, we posit
that miR‐146 may play a role in the resolution of vascular
inﬂammation and that the prolonged expression of miR‐146 is a
molecular marker of inﬂammatory ‘memory’. This is consistent
with a recent report demonstrating that miR‐146a is involved
in the resolution of T‐cell activation (Yang et al, 2012). In
endothelial cells, elevated levels of miR‐146a/b may promote
cytokine desensitization, whereby an initial cytokine treatment
blunts the intensity of a subsequent response to cytokine
exposure (Pober et al, 1986, 1987). Others have observed that
induction of miR‐146a in monocytes following exposure to LPS
promotes tolerance to this stimulus (Nahid et al, 2009; Nahid
et al, 2011). Perhaps a similar mechanism involving miR‐146a
and/or miR‐146b operates in endothelial cells to restrain
inﬂammation in response to pro‐inﬂammatory cytokines.
Such desensitizationmight serve to prevent chronic activation
of inﬂammation in the vasculature, and we anticipate that
miR‐146 expression in the endothelium may therefore play a
protective role against the development of atherosclerosis, a
chronic inﬂammatory disease. While the expression of miR‐146a
and miR‐146b is elevated in human atherosclerotic plaques
(Raitoharju et al, 2011), the function of miR‐146 in the
progression of atherosclerosis is not known.
We ﬁnd that miR‐146 restrains vascular inﬂammation by
repressing the NF‐kB and EGR pathways, which play important
roles in atherogenesis (Albrecht et al, 2010; Gareus et al, 2008;
Harja et al, 2004). Additionally, miR‐146a also targets TLR4
(Yang et al, 2011), which is expressed in several vascular and
leukocyte cell types, and has been implicated in the etiology of
atherosclerosis (den Dekker et al, 2010). We also identify HuR as
a novel target of miR‐146 and ﬁnd that HuR acts to promote
endothelial activation and leukocyte recruitment in response
to IL‐1b. A prior report demonstrated that HuR knock‐down
repressed endothelial activation in vitro in response to LPS. This
was accompanied by a reduction in the activation of NF‐kB
and an elevation of eNOS mRNA (Rhee et al, 2010). While we
also ﬁnd that knock‐down of HuR reduces the adhesion of
monocytes to IL‐1b treated endothelial cells (Fig 7D), HuR does
not regulate NF‐kB activity in IL‐1b‐treated cells (Supporting
Information Fig S8D), nor does it regulate the induction of
adhesion molecules (Fig 7F, Supporting Information Figs. S8B
and S9B). Instead HuR represses the expression of eNOS and
cells with reduced levels of HuR are not able to down‐regulate
eNOS expression in response to IL‐1b treatment (Fig 7F and G).013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1027
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Henry S. Cheng et al.Importantly, eNOS down‐regulation plays a key role in
atherogenesis (Knowles et al, 2000; Oemar et al, 1998). In
addition we show that inhibition of NO activity can rescue the
reduced leukocyte adhesion observed in HuR knock‐down cells
(Fig 7H). While HuR does not directly bind to NOS3 mRNA,
it does bind to a known positive regulator of NOS3 transcription
(Lin et al, 2005), KLF2 (Supporting Information Fig S12A),
and knock‐down of HuR results in elevated levels of KLF2
(Supporting Information Fig S12B). Finally, we ﬁnd that HuR
protein levels are reduced at the late stages of endothelial
activation (Fig 7C), suggesting that miR‐146 up‐regulation at
this stage may repress HuR, thereby forming a negative feedback
loop. MiR‐146 therefore inhibits endothelial activation by
coordinately repressing the induction of adhesion molecules
(through targeting of TRAF6/IRAK1/2) and by promoting the
expression of eNOS, an inhibitor of leukocyte adhesion (through
targeting of HuR) (Supporting Information Fig S13).
From recent discoveries it appears that a microRNA network
acts in endothelial cells to restrain inﬂammation (Fish &
Cybulsky, 2012). For example, miR‐10a levels are decreased
in regions of the mouse aorta that are susceptible to the
development of atherosclerosis (Fang et al, 2010). MiR‐10a
represses NF‐kB activity by targetingMAP kinase kinase kinase 7
(MAP3K7, also known as TAK1) and b‐transducin repeat‐
containing gene (b‐TRC), which mediate IkB degradation
(Fang et al, 2010). Additionally, TNF‐a up‐regulates miR‐31
and miR‐17‐5p, which directly repress the adhesion molecule
genes SELE and ICAM1, respectively (Suarez et al, 2010). More
recently, miR‐181b was found to repress the expression of
importin‐a3, which is required for the nuclear import of NF‐kB
proteins (Sun et al, 2012). Over‐expression of miR‐181b in the
vasculature inhibits the expression of NF‐kB‐dependent genes
and protects mice from sepsis (Sun et al, 2012). The existence
of several microRNAs that converge on the NF‐kB pathway
suggests that tight control of this pathway is crucial for the
maintenance of vascular homeostasis. Our ﬁndings have added
miR‐146a and miR‐146b to this microRNA‐mediated NF‐kB
regulatory network in the endothelium (Supporting Information
Fig S13). In addition to regulating the NF‐kB pathway, miR‐146Figure 7. HuR, a novel miR‐146 target, controls endothelial activation by reg
A. Schematic of a potential miR-146 binding site in the 30 UTR of HuR.
B. Luciferase assays utilizing wild-type (WT) or seed-mutated (Mut) HuR 30 UTR
(mean  SEM, p ¼ 0.008, t-test, n ¼ 4).
C. HuR protein levels were quantified by Western blot in cells transfected with
D. The adhesion of THP-1 cells to vehicle or IL-1b treated cells transfected with
representative experiment is shown (three replicate wells, three images per wel
IL-1b-treated HuR knock-down cells, p < 0.001.
E. THP-1 adhesion assays were performed with endothelial cells transfected wit
reduced the elevated adhesion of THP-1 to endothelial cells transfected with m
three images per well). ANOVA ¼ 0.016. Indicates a significant difference be
F. Knock-down of HuR (above) or TRAF6 (below) was performed and the induction
qRT-PCR. Expression of other inflammatory genes is indicated in Supporting Inf
contrast to TRAF6 knock-down, which strongly inhibited VCAM-1 induction. H
mean  SEM of three independent experiments. Significant p values (t-test)
G. Levels of eNOS protein were elevated in HuR knock-down cells, and eNOS wa
H. The nitric oxide inhibitor, L-NAME, negated the reduced THP-1 adhesion obse
replicate wells, three images per well). ANOVA, p < 0.0001. Indicates a sig
EMBO Mol Med (2013) 5, 1017–1034  2also controls activation of the EGR and AP‐1 pathways, which
are known to drive inﬂammatory gene expression (De Caterina
et al, 2010; Hajra et al, 2000), and miR‐146 directly targets HuR,
which promotes endothelial activation by antagonizing eNOS
expression. This implies that miR‐146 may have an even broader
anti‐inﬂammatory role than miR‐10a, miR‐31, miR‐17‐5p or
miR‐181b. Our ﬁndings suggest that strategies to enhance
miR‐146a or miR‐146b in the vasculature may be therapeutically
useful to dampen the endothelial response to inﬂammatory
cytokines, and may potentially be used to shut off the reiterative
inﬂammatory loop that drives atherogenesis or to quell the
vascular damage associated with cytokine storm in the setting
of sepsis.MATERIALS AND METHODS
Reagents used
Recombinant human IL‐1b and TNF‐a were from Invitrogen, and were
used at a concentration of 10 ng/mL. Mouse recombinant IL‐1b was
from R&D Systems. The MAP kinase inhibitor, UO126, was from Sigma–
Aldrich and was dissolved in DMSO and used at a concentration of
10 mM. L‐NAME was purchased from Sigma–Aldrich and was used at a
concentration of 0.1 mM.
Cell culture and treatments
Human umbilical vein endothelial cells (HUVEC) and media (Endo-
thelial Cell Medium with 5% FBS and Endothelial Cell Growth
Supplement) were purchased from ScienCell. Bovine aortic endothelial
cells (BAEC) and media were purchased from Lonza. Cells were used at
passages 3–8. HeLa‐S3 and THP‐1 cells were purchased from ATCC.
HeLa cells were maintained in DMEM with 10% FBS and THP‐1 cells
were maintained in RPMI1640 with L‐glutamine and 0.05 nM
b‐mercaptoethanol and 10% FBS.
Monocyte adhesion assay
THP‐1 cells were labelled with CellTracker™ Green (Invitrogen)
immediately prior to the experiment. HUVEC were cultured to
conﬂuence in 12‐well plates and were treated with IL‐1b for 4 h.ulating eNOS expression.
sequences were performed in the presence of control or miR-146a mimic
control or miR-146a mimic (left) or control or miR-146 inhibitor (right).
control or HuR siRNAs revealed that HuR promotes endothelial activation. A
l). ANOVA, p < 0.0001. Indicates a significant decrease in THP-1 adhesion in
h control or miR-146 inhibitor and control or HuR siRNA. HuR knock-down
iR-146 inhibitor. A representative experiment is shown (three replicate wells,
tween indicated groups, p < 0.05.
of adhesion molecules (typified by VCAM-1) and eNOS (NOS3) was assessed by
ormation Fig S9B. HuR knock-down did not reduce the induction of VCAM-1, in
owever, HuR knock-down significantly elevated levels of NOS3. Shown is the
are indicated above.
s not down-regulated in HuR knock-down cells treated with IL-1b.
rved in HuR knock-down cells. A representative experiment is shown (three
nificant difference between groups, p < 0.001.
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Henry S. Cheng et al.Labeled THP‐1 cells (105) were then added to each well for 90 min and
unbound cells were removed by washing with PBS. For experiments
using L‐NAME, cells were treated with IL‐1b and 0.1 mM L‐NAME for
4 h, and THP‐1 cells were allowed to adhere for 15 min. Adherent cells
were ﬁxed with 4% paraformaldehyde and imaged using a Leica
Microsystems inverted ﬂuorescent microscope (Model #DMIL) with an
Olympus DP71 camera. Adherent THP‐1 cells were quantiﬁed in three
random ﬁelds of view per well using ImageJ. Triplicate wells were
analysed for each experiment.
Transfection
HUVEC were transfected at 50% conﬂuency with control or miR‐
146a mimics (20 nM, Dharmacon), or non‐targeting control, EGR-3,
HuR or TRAF6 siRNAs (Silencer Select s4544, 4390843, s4610
or s14389, respectively, 40 nM, Invitrogen) and analysed after 24–
72 h. For inhibitor experiments, HUVEC were transfected at 90%
conﬂuency with control or miR‐146a locked‐nucleic acid (LNA)
inhibitors (20 nM, Power Inhibitors, Exiqon) and analysed 48–72 h
later. All HUVEC transfections were performed using RNAiMax
(Invitrogen). HeLa cells were transfected with plasmids and microRNA
mimics using Lipofectamine 2000 (Invitrogen; see Supporting Informa-
tion for details).
Bioinformatic analysis of miR-146a and miR-146b proximal
promoter regions
The genomic regions surrounding the miR-146a and miR-146b
transcriptional start sites were assessed for the presence of
Evolutionary Conserved Regions (ECRs) using ECR Browser (http://
ecrbrowser.dcode.org/), and rVista (http://rvista.dcode.org/) was used
to identify conserved transcription factor binding sites.
Luciferase assays and cloning
See Supporting Information for details.
Gene expression analysis
RNAwas isolated using Trizol (Invitrogen), reverse transcribed using the
High‐Capacity cDNA Reverse Transcription kit (Applied Biosystems), and
quantitative reverse‐transcriptase PCR (qRT‐PCR) was performed as
described previously (Fish et al, 2010). For analysis of pri-miR-146a and
pri-miR-146b, RNAwas treated with DNase I (Ambion) to remove traces
of genomic DNA. Real‐time PCR was conducted in triplicate using a
Roche Lightcycler 480® with Roche 480 Probes Master Mix or LC 480Figure 8. miR-146a/ mice demonstrate enhanced endothelial activation fo
A. Endothelial cells and cells in the vessel wall were isolated from the descending a
cells) andmiR-146a/b weremeasured by qRT-PCR. Expression was normalized t
vessel wall (n ¼ 4). Significant p values (t-test) are indicated above.
B. Levels of miR-146a and miR-146b were quantified by qRT-PCR in hearts from
miR-146a was >6-fold higher than miR-146b and miR-146b expression was
C. Expression of HuR mRNA was elevated in the hearts of miR-146a/ mice as
elevated levels of HuR and Traf6 (right).
D. Wild-type andmiR-146a/mice (3–4 months of age, n ¼ 4) were injected with
or 4 h. Expression of inflammatory genes was assessed by qRT-PCR. While basa
the induction of Vcam-1, Icam-1, Sele, Mcp-1, Egr-1 and Egr-3 was enhanced
Significant p values (t-test) are indicated above.
E. Expression of Vcam-1 protein was elevated after a 2 h IL-1b treatment in mi
F. Localization of Vcam-1 expression was assessed by immunofluorescence, revea
adjacent to the endothelium of miR-146a/ mice treated with IL-1b for 4 h
EMBO Mol Med (2013) 5, 1017–1034  2SYBR Green I Master (Roche) for Taqman® and Sybr green chemistries,
respectively. Data was normalized to Tata box binding protein (TBP)
or glyceraldehyde 3‐phosphate dehydrogenase (GAPDH) using the
Delta‐Delta Ct method. The primers used are indicated in Supporting
Information Table SI.
MiR‐146a and U6 were reverse‐transcribed using the Taqman®
MicroRNA Reverse Transcription kit (Applied Biosystems) and
analysed using Taqman Primer sets (Applied Biosystems). The miR‐
146a primer set did not cross react with miR‐146b (<1% cross
reactivity). Since the miR‐146b primer set from Applied Biosystems
cross‐reacted with miR‐146a, we used the miScript system (Qiagen)
for analysis of miR‐146b. MiScript primers for miR‐146b only
partially cross‐reacted with miR‐146a (<20% cross reactivity).
To quantify the number of copies of miR‐146a and miR‐146b,
comparison was made to a standard curve generated by reverse
transcribing a known amount of miR‐146a or miR‐146b mimic
(Dharmacon). The MiScript system was also used for the analysis of
other microRNAs (miR‐10a, miR‐17, miR‐31, miR‐155 and miR‐181b)
in wild‐type and miR-146a/ hearts. Expression was normalized to
miR‐126 in these experiments.
HuR immunoprecipitation
HUVECwere harvested and lysed in RIPA buffer (Santa Cruz) containing
protease inhibitors and 100 U/mL RNAse OUT (Invitrogen). Protein–
RNA complexes were isolated from 1.75 mg of total clariﬁed protein
with 5 mg of either HuR antibody (Santa Cruz, G‐8) or V5 antibody
(Invitrogen) using 60 mL protein A/G beads (Santa Cruz) by rotation at
4°C for 4 h. Beads were washed 3 in RIPA buffer and resuspended in
1 mL Trizol (Invitrogen), followed by RNA isolation.
Western blotting
Western blotting was performed as described (Fish et al, 2008). For
analysis of pERK, HUVEC were serum starved overnight (in basal
medium containing 0.1% FBS) prior to stimulation with IL‐1b (20 ng/
mL). The following antibodies were used: phospho‐ERK (p42/44Thr202/
Tyr204, Cell Signaling, 9101), ERK2 (Santa Cruz, C‐14), E‐Selectin (Santa
Cruz, H‐300), ICAM‐1 (Santa Cruz, G‐5), TRAF6 (Santa Cruz, D‐10),
eNOS [Santa Cruz, C‐20, generously provided by P. Marsden (University
of Toronto)], VCAM‐1 (for human samples; Santa Cruz, E‐10), Vcam‐1
(for mouse samples; R&D Systems, AF643), HuR (for human samples;
Santa Cruz, G‐8), HuR (for mouse samples; Santa Cruz, 3A2), GAPDH
(Santa Cruz, 0411), Actin (Sigma, A2066) and Vinculin (Santa Cruz,llowing IL‐1b treatment.
orta of wild-typemice, and expression of miR-126 (as a control for endothelial
o U6. MiR-146awas significantly enriched in the endothelium compared to the
wild-type and miR-146a/ mice (3–4 months of age, n ¼ 3). Expression of
not affected by loss of miR-146a.
assessed by qRT-PCR (left, p ¼ 0.031, t-test, n ¼ 3). Western blot revealed
PBS or 125 ng of IL-1b by tail vein injection and hearts were harvested after 2
l levels of these genes were unchanged in unstimulated mice (PBS injection),
at 2 h in IL-1b treated mice, and Sele and Icam-1 were still elevated at 4 h.
R-146a/ mice compared to wild-type mice.
ling an enhancement of Vcam-1 expression in the endothelium and in puncta
. Scale bars ¼ 20 mm.
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The paper explained
PROBLEM:
Inflammation plays a vital role in acute and chronic diseases of
the vasculature, including sepsis and atherosclerosis, respec-
tively. Therapies that directly repress vascular inflammation are
expected to impede the development of these diseases. However,
current therapies are not able to specifically suppress inflam-
matory signalling in the vasculature.
RESULTS:
We find that the miR-146 microRNA family is induced by pro-
inflammatory cytokines and acts to inhibit vascular inflamma-
tion by repressing the expression of leukocyte adhesion
molecules on the surface of endothelial cells, a process known as
endothelial activation. MiR-146 accomplishes this by repressing
both transcriptional and post-transcriptional pro-inflammatory
pathways in endothelial cells.
IMPACT:
Our findings suggest that therapies that augment miR-146
expression in the vascular endothelium may be protective
against the development of inflammatory vascular diseases. As
approaches for enhancing microRNA expression in vivo continue
to improve, it may be feasible to target vascular inflammation by
modulating the expression of miR-146 in the endothelium.
Additionally, it is possible that alterations in the levels of miR-
146 may predispose individuals to the development of vascular
inflammatory diseases.
Research Article www.embomolmed.org
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1032H‐300). HRP‐conjugated secondary antibodies were from Cell
Signaling or Santa Cruz, and blots were developed using SuperSignal
West Pico Chemiluminescence Substrate (Pierce).
Enzyme‐linked immunosorbent assay (ELISA)
MCP‐1 protein was quantiﬁed in supernatants using a Quantikine
ELISA kit from R&D Systems, according to the manufacturer’s
recommendations.
Mouse experiments
All animal protocols were approved by the Animal Care Committee at
the University Health Network (Toronto). Adult (3–4 months) wild‐type
and miR-146a/mice (on a C57/BL6 background) were injected with
100 mL of PBS or 125 ng of recombinant mouse IL‐1b (in PBS) by
intravascular injection. Hearts (including a portion of the ascending
aorta) were harvested at 2 h or 4 h post‐injection and processed for
RNA or protein analysis. For analysis of microRNA expression in the
endothelium, endothelial cells were isolated from the vessel wall using
a modiﬁed protocol (Jongstra‐Bilen et al, 2006). Brieﬂy, descending
thoracic aortae were dissected, adipose tissue was removed, and aortae
were pinned en face in ice‐cold PBS containing 1 mM aurintricarbox-
ylic acid (Sigma).Tissues were treated with 5U DNase I (Fermentas) and
Liberase TM (1:100 in Ca2þ/Mg2þ‐containing PBS, Roche) for 8 min at
37°C. Intimal cells were visualized by overlaying 0.1 mM ﬂuoresbrite
polystyrene microspheres (Polysciences). Intimal cells were scraped
gently with a 30G needle and harvested directly into RNA extraction
buffer (RNAqueous‐micro kit, Invitrogen). Endothelium‐depleted vessel
wall tissue was homogenized in RNA extraction buffer.
Immunostaining
Cryosections were stained as described (Delgado‐Olguin et al, 2012).
Primary antibodies were: FITC‐Pecam‐1 (1:200) (BD Biosciences) and
Vcam‐1 (1:100) (Proteintech). Vcam‐1was detected by incubation with
Alexa Fluor 647 Goat Anti‐Rabbit (Invitrogen). Sections were imaged
using an Eclipse Ni‐U Nikon microscope and processed using NIS‐
Elements Imaging Software. 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.Statistical analysis
Unless otherwise indicated, data represent the mean of at least three
independent experiments and error bars represent the standard error
of themean. Pair‐wise comparisons weremade using a Student’s t‐test.
Comparison of three or more groups was performed using a 1‐way
analysis of variance (ANOVA) with Newman–Keuls post hoc test. A
p‐value of 0.05 or less was considered to be statistically signiﬁcant.
In all ﬁgures ,  and  represent a p‐value of 0.05, 0.01 and
0.001, respectively.Author contributions
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